PhillipOliverCoffinMDMIA, FACP, FIDSA(He/Him)

Internal Medicine • San Francisco, CA

Addiction Medicine, Hospital Medicine/Hospitalist, Infectious Disease

Director of Substance Use Research

Join to view full profile

Dr. Coffin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Coffin's full profile

Already have an account?

Office
25 Van Ness Ave
Suite 500
San Francisco, CA 94102

Education & Training

University of WashingtonFellowship, Infectious Disease, 2009 - 2012
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2006 - 2009
University of California San Francisco School of MedicineClass of 2006

Certifications & Licensure

CA State Medical License 2012 - 2025
WA State Medical License 2009 - 2013
NY State Medical License 2007 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease
American Board of Preventive Medicine Addiction Medicine

Clinical Trials

Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals Start of enrollment: 2009 Mar 01
Completed
Phase 2
Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors Start of enrollment: 2007 May 01
Completed
Phase 2
Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM) Start of enrollment: 2007 Sep 01
Completed
Phase 1, Phase 2
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) Start of enrollment: 2012 Sep 01
Completed
Phase 2
Intermittent Naltrexone Among Polysubstance Users Start of enrollment: 2013 May 01
Completed
Phase 2
Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0) Start of enrollment: 2013 Aug 01
Completed
Phase 2
Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients Start of enrollment: 2014 Jul 01
Completed
Not Applicable
Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs Start of enrollment: 2015 Dec 01
Completed
Phase 4
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder Start of enrollment: 2017 May 05
Completed
Phase 3
Repeated-dose Behavioral Intervention to Reduce Opioid Overdose Start of enrollment: 2019 Apr 22
Completed
Not Applicable
PrEP Intervention for People Who Inject Substances and Use Methamphetamine Start of enrollment: 2021 Apr 30
Recruiting
Phase 4
Mirtazapine and Methamphetamine Drug-drug Interaction Study Start of enrollment: 2021 Jul 12
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

177 citations
Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.
Nadia Fairbairn, Phillip O. Coffin, Alexander Y. Walley
The International Journal on Drug Policy. 2017-08-01
33 citations
Substance use and drinking outcomes in Personalized Cognitive Counseling randomized trial for episodic substance-using men who have sex with men
Glenn-Milo Santos, Phillip O. Coffin, Eric Vittinghoff, Erin DeMicco, Moupali Das
Drug and Alcohol Dependence. 2014-05-01
7 citations
Social mixing and correlates of injection frequency among opioid use partnerships
Christopher Rowe, Glenn-Milo Santos, Henry F. Raymond, Phillip O. Coffin
The International Journal on Drug Policy. 2017-03-01

Authored Content

Overdose Research PubMed UpdatesJanuary 2019

Press Mentions

S.F. Is Giving ‘Chill Packs’ to Homeless Meth Users. Why It May Be a Promising InterventionAugust 26th, 2024
Medication-Based Opioid Treatment on the Rise as San Francisco Grapples with OverdosesAugust 27th, 2022
As Meth Wreaks Havoc on SF Emergency Rooms, Urgency Grows for New TreatmentsAugust 23rd, 2022
Join now to see all